The efficacy of sclerotherapy as the initial treatment in patients with bleeding from Dieulafoy’s lesion of the upper gastrointestinal tract
Surgical Endoscopy · 2024
DOI: 10.1007/s00464-024-10854-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Endoscopy, 2024. Verfasst von Qingping Ouyang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Ch…. Hauptthemen laut MEDLINE: Sclerotherapy, Gastrointestinal Hemorrhage, Hemostasis, Endoscopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Scientific Research of Health Commission of Jiangxi Province, Science and Technology Foundation of the Department of Education of Jiangxi Province.
Abstract (Originalsprache)
BACKGROUND: Dieulafoy's lesion (DL) is a rare and important cause of acute nonvariceal upper gastrointestinal bleeding (ANVUGIB), however, there is a lack of clear guidelines focus on the endoscopic hemostasis treatment for DL. Sclerotherapy, as the ANVUGIB guideline recommended endoscopic hemostasis method, is widely used in clinical practice. The aim of this study is to investigate the efficacy of sclerotherapy as the initial treatment for Dieulafoy's lesion of the upper gastrointestinal tract (UDL). METHODS: Patients with UDL who underwent the ANVUGIB standard endoscopic hemostasis between April 2007 and January 2023 were enrolled. The endoscopic therapy method was left to the discretion of the endoscopist. RESULTS: In total, 219 patients were finally obtained, with 74 (33.8%) receiving sclerotherapy and 145 (66.2%) receiving other standard endoscopic therapy. The rebleeding within 30 days was significantly lower in the sclerotherapy group compared to the other standard group (5.8% vs. 16.8%, p = 0.047). There were no significant differences between the two groups in terms of successful hemostasis rate (93.2% vs. 94.5%, p = 0.713), median number of red blood cell transfusions (3.5 vs. 4.0 units, p = 0.257), median hospital stay (8.0 vs. 8.0 days, p = 0.103), transferred to ICU rate (8.1% vs. 6.2%, p = 0.598), the need for embolization or surgery rate (12.2% vs. 9.7%, p = 0.567) and 30-day mortality (0 vs. 2.1%, p = 0.553). In addition, we found no difference in efficacy between sclerotherapy alone and combination (3.1% vs. 8.1%, p = 0.714). Further analysis revealed that thermocoagulation for hemostasis was associated with a higher rate of rebleeding (28.6% vs. 3.1%, p = 0.042) and longer hospital stay (11.5 vs. 7.5 days, p = 0.005) compared to sclerotherapy alone. CONCLUSION: Sclerotherapy represents an effective endoscopic therapy for both alone and combined use in patients with upper gastrointestinal Dieulafoy's lesion. Therefore, sclerotherapy could be considered as initial treatment in patients with bleeding of UDL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. jxmushx@126.com.
- Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. xlpan16@ncu.edu.cn.
ORCID-Profile: Xiaolin Pan
Förderung
- Scientific Research of Health Commission of Jiangxi Province
- Science and Technology Foundation of the Department of Education of Jiangxi Province
Zitieren
APA
Ouyang, Q., Xia, Y., Wang, L., Qiu, J., Zhang, Y., Ding, R., Zhu, Z., Shu, X., & Pan, X. (2024). The efficacy of sclerotherapy as the initial treatment in patients with bleeding from Dieulafoy’s lesion of the upper gastrointestinal tract. Surgical Endoscopy. https://doi.org/10.1007/s00464-024-10854-3
Vancouver
Ouyang Q, Xia Y, Wang L, Qiu J, Zhang Y, Ding R, et al. The efficacy of sclerotherapy as the initial treatment in patients with bleeding from Dieulafoy’s lesion of the upper gastrointestinal tract. Surgical Endoscopy. 2024. doi:10.1007/s00464-024-10854-3
BibTeX
@article{Ouyang2024,
author = {Ouyang, Qingping and Xia, Yanhong and Wang, Liping and Qiu, Jiayu and Zhang, Yanxia and Ding, Ruiying and Zhu, Zhenhua and Shu, Xu and Pan, Xiaolin},
title = {The efficacy of sclerotherapy as the initial treatment in patients with bleeding from Dieulafoy’s lesion of the upper gastrointestinal tract},
journal = {Surgical Endoscopy},
year = {2024},
doi = {10.1007/s00464-024-10854-3}
}
EUVIMED